Land: Indonesië
Taal: Indonesisch
Bron: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency
BETAMETHASONE DIPROPIONATE, GENTAMICIN SULFATE
ORGANON PHARMA INDONESIA TBK - Indonesia
BETAMETHASONE DIPROPIONATE, GENTAMICIN SULFATE
0,64 MG /1,70 MG
KRIM
DUS, TUBE @ 10 G
ORGANON PHARMA INDONESIA TBK - Indonesia
2021-07-17
DIPROGENTA CREAM AND OINTMENT COMPOSITION Each gram contains 0,64 mg betamethasone dipropionate equivalent to 0,5 mg betamethasone and 1,7 mg gentamicin sulfate equivalent to 1 mg gentamicin base. DESCRIPTION A combination of the corticosteroid betamethasone dipropionate and the antibiotic gentamicin sulfate with anti-inflammatory, antipruritic, vasoconstrictive and bactericidal properties, particularly against staphylococcal species. INDICATIONS For the reduce of inflammatory manifestations of corticosteroid-responsive dermatoses when complicated by secondary infection, caused by organisms susceptible to gentamicin, or when such infection is suspected. DOSAGE AND ADMINISTRATION A thin film should be applied to cover completely the affected area twice daily, in the morning and evening. Some patients may be maintained with less frequent application. PRECAUTIONS Discontinue treatment if irritation or sensitization develops. Any side effect reported following use of systemic corticosteroids may occur, especially in infants and children. Cross-allergenicity among aminoglycosides has been demonstrated. Systemic absorption of corticosteroids will increase if occlusive dressing is used or extensive areas are treated. Overgrowth of nonsusceptible organisms may occur; should superinfection develop, discontinue treatment and initiate appropriate therapy. Systemic absorption of topically applied gentamicin may be increased if extensive body surface areas are treated, especially over prolonged time periods or in the presence of dermal disruption. In these cases, the undesirable effects which occur following systemic use of gentamicin may potentially occur. Cautious use is recommended under these conditions, particularly in infants and children. Not for ophthalmic use. DISETUJUI OLEH BPOM: 25/06/2021 EREG100373VR12100265 EREG100373VR12100267 Visual disturbance may be reported with systemic and topical (including, intranasal, inhaled and intraocular) corticosteroid use. If a patient presents with symptoms such as blurred v Lees het volledige document